A comparison between Vildagliptin and Dapagliflozin in Diabetes Mellitus patients in addition to Metformi
Phase 4
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2023/02/049942
- Lead Sponsor
- Dr Bratati Sanyal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of either sex aged from 18 to 65, who are on oral Metformin therapy of 2000mg/day for type 2 diabetes mellitus for at least six months and with HbA1c values between 6.5 to 9, attending the General Medicine OPD of college of Medicine & Sagore Dutta Hospital, Kamarhati, Kolkata.
Exclusion Criteria
Pregnant and lactating women and patients planning for pregnancy in next few months.
Patients suffering from any acute illness at the time of screening.
Patients with known history of any hypersensitivity reactions from any of the study drugs.
Patients who have already enrolled for any other ongoing clinical trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacies of Vildagliptin and Dapagliflozin in terms of reduction of HbA1c from baseline. <br/ ><br>To compare the safety of Vildagliptin and Dapagliflozin <br/ ><br>Timepoint: 0, 12 weeks, 24 weeks
- Secondary Outcome Measures
Name Time Method To compare the reduction in FBS, PPBS, lipid profile, serum urea, creatinine, ACR in case of Vildagliptin and DapagliflozinTimepoint: 0, 12 weeks, 24 weeks